Parasitic lung infections.
OBJECTIVE
Global climate change and population explosion leading to changes in natural ecosystem and travel across the continents have resulted in an increase in the transmission of parasites to human beings. This review focuses on recent advancements in parasitic lung infections.


RESULTS
Invasive parasitic diseases including lung infections are increasingly being reported in patients with immunodeficiency syndromes. A recombinant kinesin-related antigen of Leishmania donovani has been validated with ELISA using urine samples for the diagnosis of visceral leishmaniasis. Pyruvate kinase deficiency has been shown to provide protection against Plasmodium falciparum infection. Intravenous artesunate is an alternative drug for the treatment of severe malaria. The best way to protect from malaria is the use of long-lasting insecticide-treated bednets. Biennial treatment with praziquantel has been found to be cost-effective treatment for control of infection with Schistosoma haematobium. Pulmonary paragonimiasis can be diagnosed by fine needle aspiration biopsy of pulmonary nodules. Strongyloides stercoralis hyperinfection can mimic accelerated idiopathic pulmonary fibrosis. Migratory nodular shadows with halos are important chest computed tomographic findings in human toxocariasis.


CONCLUSIONS
Patients with immunodeficiency syndromes (HIV infection, organ transplantation and immunosuppressive drugs, including corticosteroids) should be evaluated for early detection of parasitic lung infections.
Vijayan
Vannan Kandi
VK
Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India. vijayanvk@hotmail.com
D000977:Antiparasitic Agents / Q000627:therapeutic use; D017752:Greenhouse Effect; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008174:Lung Diseases, Parasitic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D009894:Opportunistic Infections / Q000175:diagnosis / Q000453:epidemiology* / Q000469:parasitology*; D015995:Prevalence; D012307:Risk Factors
D000977:Antiparasitic Agents; D007166:Immunosuppressive Agents